A high-profile cancer track commands attention, while wearables and IBM Watson Health come under fire.
The first days at SXSW Health went deep on entrepreneurship and the marketing thereof.
The MM&M Transforming Healthcare Conference will be held May 1 in New York City.
Novartis' Gleevec shows long-term survival benefit in study; Novo Nordisk CEO considers small acquisitions; Merck KGaA to sell biosimilars unit
The organization is now called Havas Health & You and continues to be led by Donna Murphy.
Companies form alliance to lower healthcare costs; the EMA cautions doctors on switching patients to biosimilars; analyst says Remicade suit may be settled
He instead decided to find a way to make a physician's job easier by creating a clinical messaging platform.
The results will be compiled in MM&M's 2017 Agency A-to-Z Directory, the industry's most comprehensive list of healthcare marketing and advertising agencies.
Researchers question relationship between R&D costs and drug prices; Alexa uses WebMD to answer health questions; lawmakers push GAO to investigate orphan drugs
Pharmaceutical companies often blur the lines between a drug's risks and benefits in ads, and that frustrates physicians.
GOP unveils ACA replacement; Trump is working on new drug-pricing system; researchers to study thousands of immunotherapies
The new spot for its cholesterol-lowering injection debuted last week.
Gilead exec blames PBMs for high drug prices; Google uses AI to detect signs of breast cancer; Sanofi and Regeneron drug effective in treating eczema
Pfizer and Bristol-Myers Squibb were the top spenders last year.
Linzess prescriptions increased after new DTC ads; new ACA draft is hidden from lawmakers; Roche's breast-cancer combo drug reports positive results
Ten drugmakers seek to exclude pricing information from proxy ballots; roughly 85% of patient advocacy groups get industry funding; Juno halts lead CAR-T project
The data stems from the 2017 MM&M/Guidemark Health Healthcare Marketers Trend Report.
Trump reiterates call to bring down drug prices; Novartis renews its focus on immunotherapies; a new bill would allow drugs to be imported
WPP creates WPP Health & Wellness; Publicis Health formalizes new name; 10 ways healthcare companies are testing Instagram
Valeant added 250 primary care sales reps to promote its Salix portfolio.
The joint venture pairs a communication powerhouse with a provider of defense-department-grade predictive analytics.
J&J discloses list prices for its drugs; Kite's CAR-T therapy meets study goals; healthcare providers seek to engage patients in decisionmaking
The health insurer partnered with Microsoft to use VR and AR technology to gather biometric data.
Pfizer receives subpoena over patient assistance programs; drugmakers raise prices less this January than last; lawmakers have new plan to repeal ACA
The network was previously called Publicis Healthcare Communications Group.
PBMs' use of "clawbacks" prompt lawsuits; Merck's experimental antiviral drug prevents infection; EMA recommends Novartis' lung-cancer combo drug
The Medical Advertising Hall of Fame recognized dozens of industry leaders and rising agency executives.
Harvard Pilgrim signs pay-for-performance deals with Lilly and Amgen; new advocacy group wants lower drug prices; Zykadia gets priority review
The report identifies four major issues of the 28% that were found to abuse IAB's standards.
Audit says MD Anderson Cancer Center mismanaged Watson partnership; Icahn takes stake in BMS; Sarepta sells priority review voucher to Gilead
Dennis Urbaniak has also been named chief digital officer at Havas Lynx.
Pharma industry remains focused on Alzheimer's, despite setbacks; few new diabetes drugs in development; the FDA issues complete response letter to Trevena
The campaign would require a two-fold approach: Facebook link ads and Facebook Audience Network.
Drugmakers are becoming much more cautious with their budgets, WebMD executives said.
Microsoft reenters healthcare market; Trump accuses Cummings of avoiding drug-pricing meeting; Trump says ACA replacement plan to be unveiled in March
The FDA approves Valeant's psoriasis drug; PhRMA to review its membership criteria; Lions Health announces pharma and health and wellness jury presidents
Novo Nordisk appoints new CEO, and more people moves for you to know about
Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto
Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.
More older Americans are taking at least three psychiatric drugs; Marathon to pause launch of Emflaza; Aetna and Humana call off deal
The drugmaker worked with creative agency BBDO and PR firm Marina Maher Communications to develop the campaign.
Sanofi to sell five OTC drugs to Ipsen; Teva reports 33% revenue growth in Q4; Regeneron issued subpoena about support of nonprofits
Ads promoting Merck's and Bristol-Myers Squibb's immunotherapies could signal the beginning of a new era for DTC.
The company acquired Everyday Health in December.
The new venture aims to provide clients with global reach.
Industry files petition over FDA off-label draft guidance; Marathon secures new DMD drug approval; Price confirmed as head of HHS
Court to allow Sanofi and Regeneron to market Praluent during appeal; Xarelto is effective in treating artery disease; VP advocates for right-to-try laws
Allergan said it would increase its investment in DTC after reporting slowing sales for its double-chin injection.
If generic versions by Mylan, Hikma, and Vectura are approved mid-year, GSK expects sales of Advair to be flat or decline.
The drugmaker is planning a commercial boost for its HIV-prevention drug.
Sanofi is not in a hurry to make a deal; Spicer says Trump supports Medicare drug price negotiations; HCV market is shrinking, Gilead execs say
Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.
The aim is not only to urge people to get regular eye exams, but also to maintain good health, as many other preventable diseases like diabetes can lead to vision loss.
Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer
The bill, if enacted, would publicly share information about industry payments to physician assistants and nurse practitioners.
Novo Nordisk CEO describes 'volatile' pricing environment; Lilly to cut 200 research and development jobs; pharma opts out of Super Bowl this year
Pharmaceutical and healthcare companies use a mix of corporate and brand accounts on Instagram, and some are turning to celebrity influencers.
Trial finds that Repatha reduces risk of heart attack and stroke; California measure would ban drug coupons in some cases; Takeda to limit price increases
Thirty-percent of Keytruda's U.S. sales came from its lung-cancer indication.
To drive the point home, the ads even feature an image of an actual case of shingles. The blistering red rash appears on-screen for several seconds.
Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue
A bout with Lyme disease led Yee to found a company that helps patients measure and track their breathing patterns.
A WPP insider has been tapped as CEO of WPP Health & Wellness, and Ogilvy CommonHealth chairman/CEO Matt Giegerich is stepping down.
Trump wants to speed up drug approvals; Sanofi allergy drug gets OTC approval; Lilly ends final solanezumab trial
Merck and Aetna partner in value-based drug pricing; data scientists rising in the biopharma ranks; Japanese pharma leads digital health innovation
WPP will create "Team WBA," a bespoke team that would work on traditional and digital advertising, media, and PR.
The annual awards program has added three new categories.
The drugmaker previously launched an unbranded campaign about lung-cancer biomarkers.
Diabetes patients sue drugmakers over price increases; the FTC opens Mylan investigation; Fitbit to ramp up marketing
Merck details price increases for its drugs; Trump's call to freeze federal hiring may not affect the FDA; Sanofi to settle vaccines-pricing lawsuit
BMS cuts forecast after Opdivo setbacks; diabetes death rate rises; McKesson acquires prior authorization startup
A new survey found that 34% of healthcare and pharma marketers say that the election of President Trump will not affect their marketing budgets.
A Haymarket Media survey of more than 700 client-side marcomms execs in the US reveals the shift in power will not significantly affect budgets.
J&J to buy Actelion for $30 billion; Pfizer fights advertising ban related to Advil; almost half of women with breast cancer report severe side effects
Transportation barriers can limit patient involvement in clinical trials.
Docs said patients asked about drugs from DTC ads six times in a typical week, compared to just twice a week five years ago.
Novartis forecasts slower growth in 2017; Actelion reports trial failure for PAH drug; HHS nominee Tom Price denies conflict of interest claims
Endo settles pay-for-delay charges; Trump signs order withdrawing U.S. from TPP; administration considers Patrick Soon-Shiong for healthcare role
But it may also increase the reporting burden for drugmakers.
BMS and Ono settle Keytruda patent suit; PhRMA plans to release new campaign; Trump moves forward with plans to scale back the ACA
How the retail pharmacy chain uses customer data to make its marketing messages relevant.
Many healthcare comms leaders are paying close attention to the debate between "access" to healthcare versus making it a requirement, experts say.
Pharma among top sponsors of Trump inauguration parties; AstraZeneca exec to replace GSK president of global pharmaceuticals; EpiPen rival to relaunch
The regulator is providing examples of appropriate off-label communications.
The FDA releases three documents; PBM rebates eating into drugmaker revenue: PhRMA; most oncologists on Twitter receive money from pharma
Deborah Furey will lead the agency's pilot of a new personalized marketing offering.
MM&M last year named its inaugural class of 16 Femmes and 20 Women to Watch. Who should be considered for this year's list of breakthough women?
Rep. Price to answer questions at confirmation hearing; 22 drugmakers invest in fighting disease in poor countries; FDA approves generic of Jazz's Xyrem
Endo hires new head of U.S. branded pharma, and three other people moves for you to know about.
The agency issued 11 enforcement letters last year.
Biogen to pay $1.25 billion for patents to MS drugs; Supreme Court to hear Novartis case over Zarxio delay; Merck KGaA inks big-data deal
CVS to sell generic EpiPen; FDA finalizes biosimilar naming rules; Pfizer wants to make a deal
The firm is sharing space in the City of Brotherly Love with healthcare media shop CMI.
There are dozens of players, including leaders like IBM Watson Health and Verily as well as smaller concerns, lining up to sell pharma access to some sort of data solution.
Trump says pharma is "getting away with murder"; Senate majority votes to repeal ACA; IBM Watson Health and FDA to study blockchain technology
Merck said the FDA accepted its submission of a Keytruda/chemotherapy combo drug and granted it Priority Review.
J&J's CEO may be right. Customers of all kinds are demanding change.
The FDA accepts Keytruda combo for review; Valeant offloads Dendreon and skincare brands; pharmacies feeling the squeeze from Express Scripts
DeViteri started in the newly created role this month.
The American College of Physicians said the costs of some new diabetes drugs do not always mean added benefits for patients.
- Five things for pharma marketers to know: Wednesday, March 22, 2017
- Five things for pharma marketers to know: Monday, March 20, 2017
- Novartis aims to bring first oral asthma drug to market in two decades
- Drugmakers target severe asthma patients with biologics, but payers raise pricing issue
- Five things for pharma marketers to know: Tuesday, March 21, 2017
- 2017 Healthcare Marketers Trend Report: All the data in one place
- Infographic: What's next for the point of care market
- Drugmakers again boost DTC spending, to $5.6 billion in 2016
- Publicis Health formalizes new name, promotes 3 execs
- Digital IDs become focus as drugmakers seek to track doctors' behavior online